

# Maria Queralt Salas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9368042/publications.pdf>

Version: 2024-02-01

32  
papers

337  
citations

1039880

9  
h-index

887953

17  
g-index

33  
all docs

33  
docs citations

33  
times ranked

443  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2259-2264.	2.0	66
2	Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. <i>Bone Marrow Transplantation</i> , 2020, 55, 1773-1783.	1.3	35
3	Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 60-69.	1.3	26
4	Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab. <i>European Journal of Haematology</i> , 2020, 104, 145-147.	1.1	24
5	Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2019, 103, 510-518.	1.1	19
6	Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft-versus-Host Disease Prophylaxis. <i>Clinical Hematology International</i> , 2019, 1, 105-113.	0.7	18
7	Pretransplantation EASIX predicts intensive care unit admission in allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2021, 5, 3418-3426.	2.5	17
8	Clinicopathologic features and prognostic significance of CD30 expression in <i>de novo</i> diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution. <i>Biomarkers</i> , 2020, 25, 69-75.	0.9	14
9	Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. <i>Leukemia and Lymphoma</i> , 2021, 62, 3373-3383.	0.6	12
10	Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 428.e1-428.e9.	0.6	11
11	Bloodstream Infections and Outcomes Following Allogeneic Hematopoietic Cell Transplantation: A Single-Center Study. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 50.e1-50.e8.	0.6	11
12	Reduced-intensity conditioning allogeneic transplant with dual T-cell depletion in myelofibrosis. <i>European Journal of Haematology</i> , 2019, 103, 597-606.	1.1	9
13	High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis. <i>Leukemia and Lymphoma</i> , 2020, 61, 3198-3208.	0.6	9
14	Use of Telehealth for Domiciliary Follow-up After Hematopoietic Cell Transplantation During the COVID-19 Pandemic: Prospective Pilot Study. <i>JMIR Formative Research</i> , 2021, 5, e26121.	0.7	8
15	Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2020, 104, 36-45.	1.1	7
16	PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 489.e1-489.e9.	0.6	7
17	Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1511-1519.	2.0	6
18	Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 265.e1-265.e9.	0.6	6

#	ARTICLE	IF	CITATIONS
19	Dual T Cell Depletion with Anti-Thymocyte Globulin and Post-Transplant Cyclophosphamide Results in Low Rates of Cytokine Release Syndrome in Peripheral Blood Haplo-Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e387-e388.	2.0	4
20	Isavuconazole prophylaxis against invasive fungal infections in allogeneic stem cell transplantation: A single-center experience. <i>Hematology, Transfusion and Cell Therapy</i> , 2022, 44, 440-443.	0.1	4
21	Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2021, 138, 3880-3880.	0.6	4
22	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience. <i>Cancers</i> , 2022, 14, 2673.	1.7	4
23	Impressive Graft-versus-Host Disease-Free, Relapse-Free Survival in Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning and a Combination of Antithymocyte Globulin and Post-Transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e352-e353.	2.0	3
24	Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution. <i>Leukemia and Lymphoma</i> , 2020, 61, 575-581.	0.6	3
25	Allogeneic Hematopoietic Transplantation for Multiple Myeloma in the New Drugs Era: A Platform to Cure. <i>Journal of Clinical Medicine</i> , 2020, 9, 3437.	1.0	3
26	Graft-versus-Host Disease-Free Relapse-Free Survival Definition for Patients with Nonmalignant Hematologic Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 428.	2.0	2
27	Prolactin, a potential biomarker for chronic GVHD activity. <i>European Journal of Haematology</i> , 2021, 106, 158-164.	1.1	2
28	Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis. <i>European Journal of Haematology</i> , 2021, 107, 517-528.	1.1	2
29	Effect of donor age and kinship on outcomes in haplo-identical stem cell transplantation may be modulated by GVHD prophylaxis strategies. <i>Bone Marrow Transplantation</i> , 2021, 56, 689-691.	1.3	1
30	Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT. <i>Blood</i> , 2019, 134, 3344-3344.	0.6	0
31	Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning. <i>Blood</i> , 2019, 134, 4590-4590.	0.6	0
32	Validation of Different Prognostic Scores in Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era. <i>Blood</i> , 2021, 138, 3925-3925.	0.6	0